Mapping of Italian research excellence in Neurodegenerative - Apre

Recommendations

Info

lead to generalized neurodegeneration. The aim of the project is to understand better the transport function of these two proteins in order to get insight into their causative role in these forms of neurodegeneration.
Nome Bruno Samorì Contatti E mail: bruno.samori@unibo.it Istituto/Dipartimento Laboratory of Nanoscience and Nanobiotechnology, Department of Biochemistry, University of Bologna (Italy) (http://biocfarm.unibo.it/samori/) Proposta di ricerca Area di interesse identificata Basic research Abstract According to an emerging view, the aggregation-prone proteins associated to neurodegenerative, Parkinson’s, Alzheimer’s, and Creutzfeldt-Jakob diseases, can switch back and forth between functional and amyloidogenic/prionogenic conformations. Their conformational polymorphism poses tremendous challenges to standard methods in structural biology, which mask the complexity of their behaviour by recording observables as time and ensemble averages. Single-molecule methodologies can instead follow the time trajectories of individual molecules or molecular assemblies, can map their energy landscapes, and obtain distributions of molecular properties. These capabilities can provide information about the monomeric state of an amyloidogenic protein and about the very early stages of its amyloid cascade. This information is crucially needed for the design of new drugs against Parkinson’s or Alzheimer’s disease that must be capable to target upstream of the formation of the most neurotoxic oligomeric species. In fact concerns are now growing over the possibility that more harm than cure can be created whenever the deposits in the central−nervous−system, are targeted instead: in this way their dynamic equilibrium with the oligomeric forms can be shifted back to the latter. We have recently shown that Atomic Force Microscopy-based Single Molecule Force Spectroscopy (AFM-SMFS) can single out the different monomeric conformers of α-synuclein (the intrinsically unstructured protein associated to Parkinson’s disease) and of its mutants associated to genetic PD. (1,2). So far AFM-SMFS has been the only methodology that made it possible to achieve this goal. Ongoing projects: a) The integration of AFM-SMFS with Optical tweezers (OT) (in coll. with Carlos Bustamante (UC Berkeley). b) The determination of alpha synuclein aggregation step targeted by different potential drugs or chaperons, by using an integrated approach based on AFM- and OT-SMFS, AFM-imaging, Fluorescence Polarization Spectroscopy ( in collaboration with
Page 1 and 2: Mapping of Italian research excelle
Page 3 and 4: 4. Developing competitive in “ vi
Page 5 and 6: 6. Role of neuroactive steroids in
Page 7 and 8: hinders amyloidogenesis 5. Second g
Page 9 and 10: simplex genome and Alzheimer's dise
Page 11 and 12: 2. Neuro-rehabilitation and brain f
Page 13 and 14: Nome Dr. Pier Luigi San Biagio Cont
Page 15: Abstract del progetto Titolo proget
Page 19 and 20: Nome Dr. Eugenia Polverini Contatti
Page 21 and 22: Nome Sandro Sonnino Contatti Tel. E
Page 23 and 24: Titolo progetto ubiquitin−proteas
Page 25 and 26: animal models and analytical tools
Page 27 and 28: entry; cytotoxic effects of iron ov
Page 29 and 30: Nome Daniela Tardito Contatti Tel.
Page 31 and 32: SUMOylation on the toxicity of muta
Page 33 and 34: 1. MECHANISMS OF NEURODEGENERATION
Page 35 and 36: Nome Maurizio Taglialatela, MD PhD
Page 37 and 38: Finanziamenti ricevuti Titolo proge
Page 39 and 40: Nome MARIO MARCHI Contatti marchi@p
Page 41 and 42: Nome Dr. Francesca Ruberti Contatti
Page 43 and 44: nerve growth factor eye drops: Impl
Page 45 and 46: Disease (M. Rinaldi, S. Iurescia, D
Page 47 and 48: Finanziamenti ricevuti Titolo proge
Page 49 and 50: Area di interesse identificata New
Page 51 and 52: The research group Fondazione IRCCS
Page 53 and 54: Relevant ongoing research support
Page 55 and 56: hypothesis is in line with the repo
Page 57 and 58: cooperate in the neurodegeneration
Page 59 and 60: cells and the role of the peptide i
Page 61 and 62: Nome Cristina Limatola Contatti Tel
Page 63 and 64: communication between different cel
Page 65 and 66: Mitochondrial dysfunction is emergi
Page 67 and 68:
Nome Armando Genazzani Contatti Tel
Page 69 and 70:
Nome Dr. Andrea Contestabile Contat
Page 71 and 72:
Nome LAURA GASPARINI Contatti Laura
Page 73 and 74:
Nome Michele Mazzanti Contatti mich
Page 75 and 76:
1. MECHANISMS OF NEURODEGENERATION
Page 77 and 78:
HeNe sources and a mode-locked Ti:S
Page 79 and 80:
Funding agency European Commission
Page 81 and 82:
Nome Elisabetta VEGETO Contatti Tel
Page 83 and 84:
Nome Dr. Barbara Viviani Prof. Mari
Page 85 and 86:
Nome ANGELINI - ACRAF SpA Contatti
Page 87 and 88:
• Ruolo neuroprotettivo della Tim
Page 89 and 90:
Page 91 and 92:
degeneration in PD. Although the ox
Page 93 and 94:
mitochondrial ANT. Titolo progetto
Page 95 and 96:
Titolo progetto Ente finanziatore M
Page 97 and 98:
on potential mechanisms of abnormal
Page 99 and 100:
Page 101 and 102:
Country: Italy Contact person: Paol
Page 103 and 104:
Nome Roberto Rimondini-Giorgini Con
Page 105 and 106:
Nome Rosa Maria Corbo Contatti Rosa
Page 107 and 108:
Nome Prof. LUCIA MIGLIORE Contatti
Page 109 and 110:
Nome LAURA COLOMBAIONI Contatti lau
Page 111 and 112:
Nome Roberto Maggi Contatti Tel. E
Page 113 and 114:
devoted to study the role of two ho
Page 115 and 116:
Page 117 and 118:
years old nuns and the failure of p
Page 119 and 120:
Nome Manuela MARCOLI Contatti Dipar
Page 121 and 122:
Finanziamenti ricevuti - submitted
Page 123 and 124:
or purinergic receptors (e.g. P2X7)
Page 125 and 126:
increased expression of neuronal RA
Page 127 and 128:
Titolo progetto appearance of neuro
Page 129 and 130:
Nome Cecilia Bucci Contatti Tel. +3
Page 131 and 132:
Nome Prof. Paolo Macchi, PhD Contat
Page 133 and 134:
healthy patients with PD and to hig
Page 135 and 136:
Nome Adalberto MERIGHI Contatti Pho
Page 137 and 138:
Abstract del progetto Several neuro
Page 139 and 140:
Nome Monica DiLuca Contatti Univers
Page 141 and 142:
Nome Prof. Renata Bartesaghi Contat
Page 143 and 144:
Nome Sonia Levi Contatti +39 022643
Page 145 and 146:
2. PHARMACOLOGY A- Drug Design
Page 147 and 148:
Nome Carlo Melchiorre Contatti e-ma
Page 149 and 150:
Nome Prof. Federico Da Settimo, Pro
Page 151 and 152:
Nome Alberto Cassetta Contatti Albe
Page 153 and 154:
2. PHARMACOLOGY B-Drug screening
Page 155 and 156:
Nome Iliana Ferrero Fortunati Conta
Page 157 and 158:
341 810-5 Palmieri L, Alberio S, Pi
Page 159 and 160:
2. PHARMACOLOGY C- Drug Delivery
Page 161 and 162:
Colloidal drug carriers include mic
Page 163 and 164:
o Novel peptides for the engineerin
Page 165 and 166:
y thoughtfully varying synthesis co
Page 167 and 168:
cocktails, aerosols) will be employ
Page 169 and 170:
Nome Contatti Lamberto Maffei maffe
Page 171 and 172:
Nome Prof. Aldo Andreani Contatti P
Page 173 and 174:
[4] Andreani A., Burnelli S., Grana
Page 175 and 176:
Bruno Olga Role: Co-investigator Du
Page 177 and 178:
transgenic mouse lines expressing A
Page 179 and 180:
Tg-AD mice” Ente finanziatore Pha
Page 181 and 182:
maximizes the potential for neurolo
Page 183 and 184:
NSC delivery. The aim is to use pro
Page 185 and 186:
Nome Maria P. Abbracchio Contatti T
Page 187 and 188:
Nome Mariagrazia Grilli/Pier Luigi
Page 189 and 190:
Nome Fabrizio Chiti Contatti Tel. E
Page 191 and 192:
Ente finanziatore Regione Toscana D
Page 193 and 194:
Country: Italy Contact person: Pio
Page 195 and 196:
progetto Ente finanziatore Durata p
Page 197 and 198:
Objectives. The primary objective i
Page 199 and 200:
Nome PATRIZIA BISIACCHI Contatti 04
Page 201 and 202:
Durata progetto Abstract del proget
Page 203 and 204:
Finanziamenti ricevuti Titolo proge
Page 205 and 206:
Nome Federico Schena Contatti Feder
Page 207 and 208:
Nome Prof. Enrico Granieri Contatti
Page 209 and 210:
2. PHARMACOLOGY F. Drug Pharmacogen
Page 211 and 212:
guidelines for the I.R.C.C.S. and w
Page 213 and 214:
2. PHARMACOLOGY G. Clinical studies
Page 215 and 216:
conventional and non conventional a
Page 217 and 218:
Country: Italy Contact person: Gabb
Page 219 and 220:
Country: Italy Contact person: Mica
Page 221 and 222:
Nome Valerio Carelli, MD, PhD Conta
Page 223 and 224:
process. Rev Neurosci. 2008;19(4-5)
Page 225 and 226:
Nome Prof. Roberto Lucchini Contatt
Page 227 and 228:
REFERENCES Baccarelli A, Bollati V.
Page 229 and 230:
Page 231 and 232:
Nome Giuseppe Mele (Professore Aggr
Page 233 and 234:
Nome Prof. Calogero Caruso MED04 Co
Page 235 and 236:
Roberto Monastero, MD, PhD Lab of E
Page 237 and 238:
Ente finanziatore Durata progetto A
Page 239 and 240:
Nome Prof. Carlo Caltagirone Contat
Page 241 and 242:
Nome Manservigi Roberto Contatti Te
Page 243 and 244:
Nome Luisa Benussi, Giuliano Binett
Page 245 and 246:
Nome Maria Del Zompo Contatti Phone
Page 247 and 248:
Nome Patrizia Mecocci Contatti meco
Page 249 and 250:
Nome Prof. Salvatore Monaco Contatt
Page 251 and 252:
integrated in the pipeline (see www
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
e costosa. Area di interesse identi
Page 259 and 260:
Page 261 and 262:
Contatti Flaviomariano.nobili@hsanm
Page 263 and 264:
FDG-PET. CSF assays are performed i
Page 265 and 266:
Page 267 and 268:
Nome Daniela Perani Contatti Tel. E
Page 269 and 270:
Nome Maurizio Popoli Contatti Tel.
Page 271 and 272:
Sorting, reduced Stroop Color-Word
Page 273 and 274:
the effect of caregiver support on
Page 275 and 276:
Page 277 and 278:
Nome Lucilla Parnetti Contatti Clin
Page 279 and 280:
hexosaminidase, beta-galactosidase,
Page 281 and 282:
Nome Roberta Ghidoni, Giuliano Bine
Page 283 and 284:
Referente: Prof. Carlo Ferrarese Ph
Page 285 and 286:
Nome Piero Parchi M.D., Ph.D. Conta
Page 287 and 288:
SICILIANO Analisi biochimica di par
Page 289 and 290:
Nome Laura Calzà Contatti laura.ca
Page 291 and 292:
Page 293 and 294:
We will collect systematically plas
Page 295 and 296:
frontotemporal dementia and prion d
Page 297 and 298:
Allegra MR Imager with a standard q
Page 299 and 300:
Nome Maurizio Balestrino Contatti 0
Page 301 and 302:
Page 303 and 304:
I principali progetti di ricerca at
Page 305 and 306:
particularly in tasks of episodic m
Page 307 and 308:
3. HUMAN/CLINICAL RESEARCH G. Ambie
Page 309 and 310:
Country: ITALY Contact person: Ales
Page 311 and 312:
esults are: 1) the number of patien
Page 313 and 314:
Nome Vincenzo Mario Bruno GIORGINO
show all

Mapping of Italian research excellence in Neurodegenerative - Apre

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?